Related Experiment Video

Updated: Jul 17, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss

Haiyan Shen1, Baoping Zhang, June-Ho Shin

  • 1Department of Otolaryngology, Center for Aging, Washington University, 4560 Clayton Avenue, St. Louis, MO 63110, USA.

Hearing Research
|February 13, 2007
PubMed

Insights

Calcium channel blockers, trimethadione and ethosuximide, effectively reduce noise-induced hearing loss (NIHL) in mice. These T-type blockers show promise for preventing and treating hearing damage from loud noise exposure.

Area of Science:

  • Ototolaryngology
  • Neuroscience
  • Pharmacology

Background:

  • Cochlear noise injury is a leading cause of sensorineural hearing loss.
  • Calcium dysregulation is implicated in noise-induced hearing loss (NIHL).
  • T-type calcium channel blockers are FDA-approved anti-epileptic drugs.

Purpose of the Study:

  • To investigate the efficacy of T-type calcium channel blockers in preventing and treating NIHL in mice.
  • To explore the potential of trimethadione and ethosuximide for mitigating noise-induced hearing damage.

Main Methods:

  • Mice were divided into prevention and treatment groups, receiving either trimethadione or ethosuximide before or after noise exposure.
  • Auditory brainstem recording was used to assess hearing function.
  • Hair cell and neuronal density were quantified.
  • Immunocytochemistry and RT-PCR were performed to investigate the mechanism of action.

Main Results:

  • Trimethadione significantly reduced NIHL when administered before noise exposure.
  • Both trimethadione and ethosuximide were effective in reducing NIHL when given after noise exposure.
  • Protection was observed to be gender-dependent, with males benefiting more.
  • Preservation of outer hair cells and neuronal density correlated with protection.
  • Evidence suggests T-type blockers act directly on cochlear Ca(v)3 calcium channels.

Conclusions:

  • T-type calcium channel blockers demonstrate potential for both prevention and treatment of NIHL.
  • These findings support further clinical investigation of trimethadione and ethosuximide for managing noise-induced hearing loss.

More Related Videos

Modified Experimental Conditions for Noise-Induced Hearing Loss in Mice and Assessment of Hearing Function and Outer Hair Cell Damage07:13

Modified Experimental Conditions for Noise-Induced Hearing Loss in Mice and Assessment of Hearing Function and Outer Hair Cell Damage

Published on: February 10, 2023

Cochlear Surface Preparation in the Adult Mouse09:51

Cochlear Surface Preparation in the Adult Mouse

Published on: November 6, 2019

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...